Opportunities and challenges in mobile phlebotomy and self-sampling for precision chemotherapy dosing in clinical trials

We will present a case study demonstrating how chemotherapy exposure measurement via patient-centric sampling can drive personalized, more effective, and safer cancer treatments.

Chemotherapy dosages are often prescribed based on body surface area (BSA), an outdated method that doesn’t consider individual differences in drug metabolism. This can lead to underdosing or overdosing, reducing treatment efficacy or causing toxic side effects. In this presentation, we will introduce True Dose’s patented technology, designed to measure precise drug levels through patient-centric self-sampling. We’ll discuss how this approach personalizes treatment, linking drug exposure to side effects, and leveraging both venous and capillary blood samples via mobile phlebotomy. Our goal is to revolutionize diagnostics in chemotherapy to increase precision and improve patient outcomes.

Of interest to:

Clinical researchers and trial designers seeking to improve precision medicine in cancer treatment.
Oncologists and healthcare providers aiming to offer personalized chemotherapy dosing.
Clinical trial professionals focused on patient recruitment, retention, and improving trial participation rates.
Developers of medical devices and diagnostic tools who are interested in integrating patient-centric sampling methods.
Pharmacologists and geneticists exploring drug metabolism and the role of pharmacogenomics in tailoring treatments.

Your details

By submitting this form you are agreeing to our Terms & Conditions and Privacy Policy, and agree to receiving relevant emails from The Evidence Base about the latest news and editorial features.

Terms & Conditions

I agree to receive third party emails to keep me informed of relevant products and services relevant to my industry.

I agree for my registration data to be transferred to the lead partner organization (PCSIG).

Subscribing to

Confirm sign-up

What you will learn:

How True Dose’s at-home sampling technology is transforming precision medicine and improving chemotherapy dosing accuracy.
The limitations of body surface area (BSA) dosing and how personalized drug exposure measurement can solve this challenge.
A case study on linking chemotherapy dose concentrations with patient side effects using patient-centric blood sampling.
The benefits and obstacles of incorporating mobile phlebotomy and self-sampling techniques in clinical trials.
How integrating True Dose technology reduces patient burden, increases participation, and delivers personalized treatment based on metabolic and genetic factors.

Speakers:

Elham Hedayati
Senior lecturer & Associate Professor of Oncology | Senior Consultant in Clinical Oncology | Co-founder of TrueDose AB, Karolinsia Institute/Karolinska University Hospital

Elham Hedayati is a clinical researcher, senior lecturer in oncology, and senior oncologist at Karolinska Institutet and Karolinska University Hospital. Her work focuses on breast cancer research, particularly therapeutic drug monitoring to enhance drug efficacy and reduce treatment toxicity. She earned her PhD in 2012 from Karolinska Institutet, and became a docent in oncology in 2022. Elham is head of clinical trials at Karolinska Centre for Clinical Studies and co-founder of True Dose AB, with funding support from the Swedish Cancer Society, Vinnova, and Bröstcancerförbundet.

Sofie Sibia
Head of phase 1 clinical unit, Karolinska University Hospital

I have worked in various strategic roles, focusing on expanding opportunities for clinical studies and improving patient access. My experience spans both the public and private sectors, where I have developed and implemented initiatives to enhance the availability of clinical trials. With a strong background in molecular biology, I bring a deep understanding of the scientific and operational aspects necessary for driving innovation and success in clinical research.

Moderated by:

Neil Spooner
Founder, PCSIG

Neil is the Founder of Spooner Bioanalytical Solutions, helping companies to integrate biological fluid microsampling, and patient centric sampling and analysis into workflows. He also works with organisations to develop technologies and introduce them to the market. Neil also assists organisations with their understanding of emerging trends in the pharmaceutical industry and bioanalysis. Neil is a Senior Visiting Research Fellow at the University of Hertfordshire, Editor in Chief of the journal, Bioanalysis, Founder of the Patient Centric Sampling Interest Group and Co-Chair of the Reid Bioanalytical Forum. He has published over 70 peer reviewed manuscripts and delivered over 50 podium presentations.

Share this webinar